Long-Term Safety, Tolerability and Survival in Patients with Pulmonary Arterial Hypertension Treated with Macitentan: Results from the SERAPHIN Open-Label Extension

INTRODUCTION: In SERAPHIN, a long-term, event-driven, double-blind randomised controlled trial in pulmonary arterial hypertension (PAH), macitentan 10 mg significantly reduced the risk of morbidity/mortality compared with placebo. Its open-label extension study (SERAPHIN OL) further assessed long-te...

Descripción completa

Detalles Bibliográficos
Autores principales: Souza, Rogério, Delcroix, Marion, Galié, Nazzareno, Jansa, Pavel, Mehta, Sanjay, Pulido, Tomás, Rubin, Lewis, Sastry, B. K. S., Simonneau, Gérald, Sitbon, Olivier, Torbicki, Adam, Boyanova, Neli, Chamitava, Liliya, Stein, Claudia, Channick, Richard N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2022
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9402744/
https://www.ncbi.nlm.nih.gov/pubmed/35819570
http://dx.doi.org/10.1007/s12325-022-02199-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9402744/
https://www.ncbi.nlm.nih.gov/pubmed/35819570
http://dx.doi.org/10.1007/s12325-022-02199-x

Ejemplares similares